Amendments to the Claims

Please amend the claims as shown in the following listing of claims.

Listing of Claims

Claims 1-30 (Cancelled)

31. (Currently Amended) A pharmaceutical composition for percutaneous administration ~~according to claim 28, wherein the pharmaceutical composition comprises~~ comprising: (a) about 0.001% to 1.0 % by weight of 4-hydroxy tamoxifen, (b) about 0.5% to 2% by weight of isopropyl myristate, (c) about 65% to 75% by weight of alcohol, (d) about 20% to 35% by weight of aqueous vehicle, and (e) about 1.0% to 5% by weight of gelling agent, wherein the percentage of components are weight to weight of the composition.

32. (Original) A composition according to claim 31, wherein the 4-hydroxy tamoxifen constitutes about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.10% by weight of the composition.

33. (Original) A composition according to claim 31, wherein the isopropyl myristate constitutes about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% or 2.0% by weight of the composition.

34. (Original) A composition according to claim 31, wherein the alcohol is ethanol or isopropanol, and constitutes about 65% to 75% by weight of the composition.

35. (Original) A composition according to claim 31, wherein the aqueous vehicle is a phosphate buffered solution, and constitutes about 25% to 35% by weight of the composition.

36. (Original) A composition according to claim 31, wherein the gelling agent is a polyacrylic acid, hydroxypropylcellulose or other cellulose derivative, and constitutes about 1.0% to 5% by weight of the composition.

Claim 37 (Canceled)

38. (Original) A composition according to claim 31, which is packaged in a unit dose packet or in a multiple dose container with a metered pump.

39. (Currently Amended) A pharmaceutical composition for percutaneous administration comprising a pharmaceutically active agent ~~and about 0.5% to 2% by weight of isopropyl myristate, wherein the pharmaceutically active agent~~ that consists of 4-hydroxy tamoxifen, wherein the pharmaceutical composition comprises: (a) about 0.001% to 1.0 % by weight of 4-hydroxy tamoxifen, (b) about 0.5% to 2% by weight of isopropyl myristate, (c) about 65% to 75% by weight of alcohol, (d) about 20% to 35% by weight of aqueous vehicle, and (e) about 1.0% to 5% by weight of gelling agent, wherein the percentage of components are weight to weight of the composition.

Claims 40-42 (Canceled)

43. (Currently Amended) A composition according to claim 39 ~~42~~, wherein the 4-hydroxy tamoxifen constitutes about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.10% by weight of the composition.

44. (Currently Amended) A composition according to claim 39 ~~42~~, wherein the isopropyl myristate constitutes about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% or 2.0% by weight of the composition.

45. (Currently Amended) A composition according to claim 39 ~~42~~, wherein the alcohol is ethanol or isopropanol, and constitutes about 65% to 75% by weight of the composition.

46. (Currently Amended) A composition according to claim 39 ~~42~~, wherein the aqueous vehicle is a phosphate buffered solution, and constitutes about 25% to 35% by weight of the composition.

47. (Currently Amended) A composition according to claim 39 ~~42~~, wherein the

gelling agent is a polyacrylic acid, hydroxypropylcellulose or other cellulose derivative, and constitutes about 1.0% to 5% by weight of the composition.

48. (Currently Amended) A composition according to claim 39 ~~42~~, which is packaged in a unit dose packet or in a multiple dose container with a metered pump.